JIC
CTIC

Johnson Investment Counsel’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Johnson Investment Counsel’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,009
Closed -$48K – 631
2019
Q1 		$48K Buy
50,009
+9
+0% +$9 ﹤0.01% 596
2018
Q4 		$36K Hold
50,000
– – ﹤0.01% 597
2018
Q3 		$108K Buy
+50,000
New +$124K ﹤0.01% 625

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Johnson Investment Counsel's CTIC Position: Q2 2019 in Review

Johnson Investment Counsel sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2019, closing a stake of 50,009 shares — an estimated $48K sold.

Johnson Investment Counsel first reported a position in CTIC in Q3 2018 and held it in 3 quarters. The position peaked at $108K in Q3 2018. 57 funds tracked by Wall St. Rank hold CTIC as of Q2 2019.

  • Johnson Investment Counsel reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2019 after selling out during the quarter.
  • Johnson Investment Counsel sold 50,009 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2019, an estimated $48K.
  • Johnson Investment Counsel first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2018 and held it in 3 quarters.
  • Johnson Investment Counsel's CTI BioPharma Corp. (DE) Common Stock position peaked at $108K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2019.

Based on Johnson Investment Counsel's 13F filing for Q2 2019, filed 14 Aug 2019.